Mucocutaneous toxicities from MEK inhibitors: A scoping review of the literature Review
| Authors: | Iriarte, C.; Yeh, J. E.; Alloo, A.; Boull, C.; Carlberg, V. M.; Coughlin, C. C.; Lara-Corrales, I.; Levy, R.; Nguyen, C. V.; Oza, V. S.; Patel, A. B.; Rotemberg, V.; Shah, S. D.; Zheng, L.; Miller, C. H.; Hlobik, M.; Daigneault, J.; Choi, J. N.; Huang, J. T.; Vivar, K. L. |
| Review Title: | Mucocutaneous toxicities from MEK inhibitors: A scoping review of the literature |
| Abstract: | Background: MEK inhibitors cause a wide spectrum of mucocutaneous toxicities which can delay or interrupt life-saving therapy. Purpose: To summarize the morphology, incidence, and clinical presentation of mucocutaneous toxicities from MEK inhibitors via a scoping review of the literature. Methods: We conducted a scoping review of the published literature, including clinical trials, retrospective and prospective studies, reviews, and case reports and series. All included literature was analyzed by a panel of pediatric and adult oncodermatologists. Results: Of 1626 initial citations, 227 articles met final inclusion criteria. Our review identified follicular reactions, ocular toxicities, xerosis, eczematous dermatitis, edema, and paronychia as the most common mucocutaneous side effects from MEK inhibitor therapy. Grade 1 and 2 reactions were the most prevalent and were typically managed while continuing treatment; however, grade 3 toxicities requiring dose reductions or treatment interruptions were also reported. Conclusion: Mucocutaneous toxicities to MEK inhibitor therapy are common and most often mild in severity. Early recognition and treatment can mitigate disruptions in oncologic therapy. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. |
| Keywords: | clinical feature; review; drug dose reduction; skin toxicity; antineoplastic agents; skin manifestation; antineoplastic agent; neoplasm; neoplasms; edema; drug eruption; protein kinase inhibitor; pruritus; protein kinase inhibitors; disease severity; severity of illness index; acne; peripheral edema; eye disease; drug therapy; alopecia; photosensitivity; eye toxicity; urticaria; drug eruptions; paronychia; xerosis; targeted therapies; acneiform eruptions; etiology; mek inhibitors; hypertrichosis; mapk pathway; cutaneous toxicities; supportive oncodermatology; folliculitis; mitogen activated protein kinase kinase inhibitor; pimasertib; eczema; humans; human; binimetinib; treatment interruption |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 32 |
| Issue: | 9 |
| ISSN: | 0941-4355 |
| Publisher: | Springer Verlag |
| Date Published: | 2024-09-01 |
| Start Page: | 610 |
| Language: | English |
| DOI: | 10.1007/s00520-024-08810-x |
| PUBMED: | 39174797 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
